Phio Pharmaceuticals Corp., a publicly traded biotech firm based in Marlborough, on Thursday named the chairman of its board, Robert Bitterman, to serve as interim executive chairman, leading all aspects of the company’s operations.
Bitterman, who has served on the company’s board since 2012, is assuming the duties of principal executive officer, which Geert Cauwenbergh had assumed after the departure of former president and CEO Gerrit Dispersyn in May.
The executive search for a permanent CEO is ongoing, according to an email to WBJ from the Phio investor relations department.
Phio Pharmaceuticals is a biotechnology company developing a therapeutic platform to use the body’s immune system to fight cancerous tumors.
